Cytokines related to tumor necrosis factor (TNF) provide a communication network essential
for coordinating multiple cell types into an effective host defense system against pathogens …

TNF blockers are highly efficacious at dampening inflammation and reducing symptoms in
rheumatic diseases such as rheumatoid arthritis, psoriatic arthritis and ankylosing …

Cytolytic activity by CD8+ cytotoxic T lymphocytes (CTLs) is a powerful strategy for the
elimination of intracellular pathogens and tumor cells. The destructive capacity of CTLs is …

Immune checkpoint inhibitor treatment has the potential to prolong survival in non-small cell
lung cancer (NSCLC), however, some of the patients develop resistance following initial …

Clinical response to chimeric antigen receptor (CAR) T cell therapy is correlated with CAR T
cell persistence, especially for CAR T cells that target CD19+ hematologic malignancies. 4 …

Inhibitors of tumour necrosis factor (TNF) are among the most successful protein-based
drugs (biologics) and have proven to be clinically efficacious at reducing inflammation …

Costimulatory signals initiated by the interaction between the tumor necrosis factor (TNF)
ligand and cognate TNF receptor (TNFR) superfamilies promote clonal expansion …

Over the past decade, our understanding of cancer immunotherapy has evolved from
assessing peripheral responses in the blood to monitoring changes in the tumour …

T and natural killer (NK) lymphocytes are considered the main effector players in the
immune response against tumors. Full activation of T and NK lymphocytes requires the …

The tumor necrosis factor receptor (TNF-R)-associated factor (TRAF) family of intracellular
proteins were originally identified as signaling adaptors that bind directly to the cytoplasmic …